Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Abstract

The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment of heart failure of any aetiology.

1 . A method of treating heart failure with the reduction of side effects, said method comprising the steps of administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising cilobradine or a pharmaceutically acceptable salt thereof, together with a pharmaceutically suitable carrier.  
   
   
       2 . The method of  claim 1  wherein the galenical formulation of the pharmaceutical composition is selected from a tablet, a drinking solution, a capsule, a suppository or an injectable formulation.  
   
   
       3 . The method of  claim 2  wherein the galenical formulation of the pharmaceutical composition is a tablet.  
   
   
       4 . The method of  claim 2  wherein the galenical formulation of the pharmaceutical composition is a drinking solution.  
   
   
       5 . The method of  claim 1  wherein the pharmaceutical composition is administered daily.  
   
   
       6 . The method of  claim 5  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.01 and 20 mg/kg body weight.  
   
   
       7 . The method of  claim 5  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.05 and 5 mg/kg body weight.  
   
   
       8 . The method of  claim 5  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 2.5 mg/kg body weight.  
   
   
       9 . The method according to  claim 5  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 1 mg/kg body weight.  
   
   
       10 . The method of  claim 5  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 0.75 mg/kg body weight.  
   
   
       11 . The method of  claim 1  wherein the treatment of heart failure is performed in combination with diuretics, cardiac glycosides, ACE inhibitors, ARBs, vasodilators, beta blockers, or inotropes.  
   
   
       12 . The method of  claim 1  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.01 and 20 mg/kg body weight.  
   
   
       13 . The method of  claim 12  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.05 and 5 mg/kg body weight.  
   
   
       14 . The method of  claim 12  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 2.5 mg/kg body weight.  
   
   
       15 . The method according to  claim 12  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 1 mg/kg body weight.  
   
   
       16 . The method of  claim 12  wherein the administered dose of cilobradine or its pharmaceutically acceptable salt is between 0.1 and 0.75 mg/kg body weight.